Tags

Type your tag names separated by a space and hit enter

Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson's Disease.
Curr Pharm Des. 2018; 24(39):4693-4701.CP

Abstract

Parkinson's disease is the second most common neurodegenerative disorder in adults over the age of 65. The characteristic symptoms of Parkinson's disease, such as resting tremor, muscular rigidity, bradykinesia, postural instability and gait imbalance, are thought to be a result of the progressive degeneration of the dopaminergic neurons of the substantia nigra compacta, resulting in insufficient dopamine integrated signalling on GABAergic medium spiny neurons in the striatum. Despite tremendous research, the molecular mechanisms underlying the pathogenesis of neurodegeneration in Parkinson's disease have remained largely unknown. Although a variety of possible pathogenic mechanisms have been proposed over the years, including excessive release of oxygen free radicals, impairment of mitochondrial function, loss of trophic support, abnormal kinase activity, disruption of calcium homeostasis, dysfunction of protein degradation and neuroinflammation, the pathogenesis is still largely uncertain, and there is currently no effective cure for Parkinson's disease. To develop potential therapies for Parkinson's disease, inflammatory processes, mitochondrial dynamics, oxidative stress, production of reactive aldehydes, excitotoxicity and synucleinopathies are to be targeted. In this respect, vasoactive intestinal peptide has beneficial effects that provide an advantage for the treatment of Parkinson's disease. Vasoactive intestinal peptide is a major neuropeptide-neurotransmitter having antioxidant, anti-inflammatory, neurotropic, neuromodulator, and anti-apoptotic properties. In addition to its direct neuroprotective actions regulating the activity of astrocytes, microglia and brain mast cells, it also plays important roles for neuronal adaptation, maintenance and survival.

Authors+Show Affiliations

Eskisehir Osmangazi University, Medical Faculty, Department of Physiology and Neurophysiology Eskisehir 26480, Turkey.Eskisehir Osmangazi University, Medical Faculty, Department of Physiology and Neurophysiology Eskisehir 26480, Turkey.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

30636594

Citation

Korkmaz, Orhan Tansel, and Neşe Tunçel. "Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson's Disease." Current Pharmaceutical Design, vol. 24, no. 39, 2018, pp. 4693-4701.
Korkmaz OT, Tunçel N. Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson's Disease. Curr Pharm Des. 2018;24(39):4693-4701.
Korkmaz, O. T., & Tunçel, N. (2018). Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson's Disease. Current Pharmaceutical Design, 24(39), 4693-4701. https://doi.org/10.2174/1381612825666190111150953
Korkmaz OT, Tunçel N. Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson's Disease. Curr Pharm Des. 2018;24(39):4693-4701. PubMed PMID: 30636594.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson's Disease. AU - Korkmaz,Orhan Tansel, AU - Tunçel,Neşe, PY - 2018/09/07/received PY - 2019/01/01/revised PY - 2019/01/02/accepted PY - 2019/1/15/pubmed PY - 2019/11/22/medline PY - 2019/1/15/entrez KW - 6-hydroxydopamine KW - Alpha-synuclein KW - Parkinson's disease KW - inflammation KW - oxidative stress KW - vasoactive intestinal peptide (VIP). SP - 4693 EP - 4701 JF - Current pharmaceutical design JO - Curr Pharm Des VL - 24 IS - 39 N2 - Parkinson's disease is the second most common neurodegenerative disorder in adults over the age of 65. The characteristic symptoms of Parkinson's disease, such as resting tremor, muscular rigidity, bradykinesia, postural instability and gait imbalance, are thought to be a result of the progressive degeneration of the dopaminergic neurons of the substantia nigra compacta, resulting in insufficient dopamine integrated signalling on GABAergic medium spiny neurons in the striatum. Despite tremendous research, the molecular mechanisms underlying the pathogenesis of neurodegeneration in Parkinson's disease have remained largely unknown. Although a variety of possible pathogenic mechanisms have been proposed over the years, including excessive release of oxygen free radicals, impairment of mitochondrial function, loss of trophic support, abnormal kinase activity, disruption of calcium homeostasis, dysfunction of protein degradation and neuroinflammation, the pathogenesis is still largely uncertain, and there is currently no effective cure for Parkinson's disease. To develop potential therapies for Parkinson's disease, inflammatory processes, mitochondrial dynamics, oxidative stress, production of reactive aldehydes, excitotoxicity and synucleinopathies are to be targeted. In this respect, vasoactive intestinal peptide has beneficial effects that provide an advantage for the treatment of Parkinson's disease. Vasoactive intestinal peptide is a major neuropeptide-neurotransmitter having antioxidant, anti-inflammatory, neurotropic, neuromodulator, and anti-apoptotic properties. In addition to its direct neuroprotective actions regulating the activity of astrocytes, microglia and brain mast cells, it also plays important roles for neuronal adaptation, maintenance and survival. SN - 1873-4286 UR - https://www.unboundmedicine.com/medline/citation/30636594/Advantages_of_Vasoactive_Intestinal_Peptide_for_the_Future_Treatment_of_Parkinson's_Disease_ DB - PRIME DP - Unbound Medicine ER -